Padcev Sales Exceed Expectations As Seattle Genetics Pursues Earlier Indications
The bladder cancer drug delivered $34.5m in its first full quarter of sales – four times analyst consensus for Q1 – and Padcev’s market may grow rapidly based on results from ongoing studies.
You may also be interested in...
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.